Forbes July 24, 2020
In fact, the pandemic has shown that both sides must win.
Without new medicines the country will suffer terrible loss personally, socially and economically. However, the biopharmaceutical industry cannot defeat disease—be it Covid-19 or cancer— if the health-care system cannot deliver treatment to everyone in need.
The pricing debate centers around two separate but related issues:
How much do new drugs cost to make, why, and what returns does industry need to sustain innovation?
What can be done to improve patient access to powerful, but expensive, new drugs without discouraging innovation?
Battle lines are not at all clear, but passions run high. Observers hailed Gilead’s price of $3,120 for Remdesivir, the first drug approved to...
Today's Sponsors
Today's Sponsor